S Vasavanonda
Overview
Explore the profile of S Vasavanonda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sham H, Betebenner D, Herrin T, Kumar G, Saldivar A, Vasavanonda S, et al.
Bioorg Med Chem Lett
. 2001 May;
11(11):1351-3.
PMID: 11378352
The HIV protease inhibitor ABT-378 (Lopinavir) is metabolized rapidly and extensively by CYP-3A4 catalyzed oxidation. Three of the major metabolites identified were synthesized and their antiviral (HIV) activities determined.
2.
Chen X, Kempf D, Sham H, GREEN B, Molla A, Korneyeva M, et al.
Bioorg Med Chem Lett
. 1999 Feb;
8(24):3531-6.
PMID: 9934466
The 2-isopropyl thiazolyl group is a highly optimized P3 ligand for C2 symmetry-based HIV protease inhibitors, as exemplified in the drug ritonavir. Here we report that incorporation of this P3...
3.
Sham H, Kempf D, Molla A, Marsh K, Kumar G, Chen C, et al.
Antimicrob Agents Chemother
. 1998 Dec;
42(12):3218-24.
PMID: 9835517
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using...
4.
Molla A, Vasavanonda S, Kumar G, Sham H, Johnson M, Grabowski B, et al.
Virology
. 1998 Oct;
250(2):255-62.
PMID: 9792836
The potency of therapeutic regimens containing human immunodeficiency virus (HIV) protease inhibitors is related to the ability to maintain concentrations of drug in the plasma of patients that are sufficient...
5.
Kempf D, Sham H, Marsh K, Flentge C, Betebenner D, GREEN B, et al.
J Med Chem
. 1998 Mar;
41(4):602-17.
PMID: 9484509
The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral...
6.
Sham H, Zhao C, Marsh K, Betebenner D, Lin S, Rosenbrook Jr W, et al.
Biochem Biophys Res Commun
. 1996 Aug;
225(2):436-40.
PMID: 8753780
A series of novel, azacyclic ureas which are highly potent inhibitors of the HIV-1 protease (IC50 = 4.1 to < 0.5 nM) were synthesized. Aqueous solubilities of this series of...
7.
Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper P, Mo H, et al.
Nat Med
. 1996 Jul;
2(7):760-6.
PMID: 8673921
Analysis of the HIV protease gene from the plasma of HIV-infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at...
8.
Sham H, Zhao C, Stewart K, Betebenner D, Lin S, Park C, et al.
J Med Chem
. 1996 Jan;
39(2):392-7.
PMID: 8558507
The design, synthesis, and molecular modeling studies of a novel series of azacyclic ureas, which are inhibitors of human immunodeficiency virus type 1 (HIV-1) protease that incorporate different ligands for...
9.
Sham H, Zhao C, Marsh K, Betebenner D, Lin S, McDonald E, et al.
Biochem Biophys Res Commun
. 1995 Jun;
211(1):159-65.
PMID: 7779082
A series of novel pseudo-symmetrical and unsymmetrical inhibitors based on the backbone modification of a peptidomimetic were synthesized and found to be highly potent inhibitors of the HIV-1 protease (IC50...
10.
Kempf D, Marsh K, Denissen J, McDonald E, Vasavanonda S, Flentge C, et al.
Proc Natl Acad Sci U S A
. 1995 Mar;
92(7):2484-8.
PMID: 7708670
Examination of the structural basis for antiviral activity, oral pharmacokinetics, and hepatic metabolism among a series of symmetry-based inhibitors of the human immunodeficiency virus (HIV) protease led to the discovery...